Abstract
A 56-year-old man with diabetes mellitus and cadaveric renal transplantation had vancomycin-resistant Enterococcus faecium tricuspid valve endocarditis. Relapse followed 6 weeks of treatment with intravenous gentamicin and high-dose ampicillin. On the basis of previous data suggesting the potential for synergistic activity of quinupristin/dalfopristin plus high-dose ampicillin, therapy with this combination was administered for 63 days. Cure was achieved and later confirmed at 2-year follow-up.
MeSH terms
-
Ampicillin / therapeutic use
-
Anti-Bacterial Agents / therapeutic use
-
Bacteremia / drug therapy
-
Bacteremia / immunology
-
Bacteremia / microbiology*
-
Diabetes Mellitus, Type 1 / complications
-
Drug Resistance, Bacterial
-
Drug Therapy, Combination / therapeutic use
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / immunology
-
Endocarditis, Bacterial / microbiology*
-
Enterococcus faecium*
-
Gentamicins / therapeutic use
-
Gram-Positive Bacterial Infections / drug therapy
-
Gram-Positive Bacterial Infections / immunology
-
Gram-Positive Bacterial Infections / microbiology*
-
Humans
-
Immunocompromised Host* / immunology
-
Kidney Transplantation / adverse effects
-
Kidney Transplantation / immunology
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Penicillins / therapeutic use
-
Recurrence
-
Treatment Outcome
-
Vancomycin Resistance*
-
Virginiamycin / analogs & derivatives*
-
Virginiamycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Gentamicins
-
Penicillins
-
Virginiamycin
-
quinupristin
-
Ampicillin
-
dalfopristin